1. Pink Sheet
  2. >>Vaccines

Takeda's Dengue Vaccine Candidate Aims To Avoid Dengvaxia Problems

 
• By Brenda Sandburg

TAK-003 is designed to be effective in those never exposed to dengue; Takeda expects Phase III results by end of 2018.

Dengue virus vaccine

Sanofi's announcement last month that its Dengvaxia dengue vaccine may worsen the illness in vaccinated individuals who have not previously had dengue infection raised concerns about use of the vaccine. While Sanofi is advising caution in administering its product, Takeda Pharmaceutical Co. Ltd. has designed its candidate vaccine with the goal to have it be effective regardless of prior exposure.

The Pink Sheet spoke with Derek Wallace, the head of Takeda's global dengue program, about what impact the findings might have on the development of Takeda's dengue vaccine candidate TAK-003, which like Dengvaxia is a live-attenuated tetravalent vaccine

More from Vaccines

Moderna Pivots To Increase Focus On Cancer Amid US Vaccine Policy Changes

 
• By Joseph Haas

During its first quarter earnings call, Moderna avoided criticizing vaccine policy changes, but de-emphasized its flu/COVID-19 vaccine for those under age 50 and prioritized cancer programs.

How States And Courts Could Insulate America From An Anti-Vaccine Executive Branch

 
• By Sarah Karlin-Smith

The mood at the World Vaccines Congress in Washington, D.C. was bleak given Robert F. Kennedy Jr.’s rise to lead the Trump Administration’s Health and Human Services Department, but vaccine lawyers offered an optimistic outlook and ideas for countering his vaccine agenda.

Maybe In May: US FDA Calls Coming On Moderna Next-Gen COVID-19 Vaccine, AbbVie’s Big ADC Bet

 
• By Bridget Silverman

The 31 May goal date for Moderna’s next-generation COVID-19 vaccine looms over the month, but the US FDA's decision lineup includes three more novel agents, including AbbVie's Teliso-V antibody-drug conjugate, as well as supplemental indications like GSK's bid for Nucala in COPD.

Updated: Makary Backs New Novavax COVID-19 Trial, Political Officials Take Over Product Review

 
• By Sarah Karlin-Smith

In an unusual move, Tracy Beth Høeg, a special assistant to FDA Commissioner Martin Makary, is leading the continued negotiations on Novavax’s delayed COVID-19 vaccine approval.

More from Pink Sheet